Cost-effectiveness analysis of germline brca mutation testing and olaparib treatment in metastatic breast cancer: An evaluation of codependent technologies
Author(s)
Tuffaha, H
Scuffham, P
Griffith University Author(s)
Year published
2019
Metadata
Show full item recordAbstract
Genetic testing for a germline BRCA mutation in women with HER2-negative metastatic breast cancer (MBC) can guide targeted treatment with PARP inhibitors (e.g. olaparib) and inform cancer prevention strategies (e.g., risk-reducing surgery) for family members of women who test positive. Unlike BRCA testing in localised breast cancer, the cost-effectiveness of genetic testing in MBC is unknown. This study aimed to evaluate the cost-effectiveness of BRCA testing in women with MBC to guide olaparib treatment.Genetic testing for a germline BRCA mutation in women with HER2-negative metastatic breast cancer (MBC) can guide targeted treatment with PARP inhibitors (e.g. olaparib) and inform cancer prevention strategies (e.g., risk-reducing surgery) for family members of women who test positive. Unlike BRCA testing in localised breast cancer, the cost-effectiveness of genetic testing in MBC is unknown. This study aimed to evaluate the cost-effectiveness of BRCA testing in women with MBC to guide olaparib treatment.
View less >
View less >
Conference Title
VALUE IN HEALTH
Volume
22
Issue
Supplement 3
Funder(s)
NHMRC
Grant identifier(s)
APP1121232
Subject
Applied economics
Social Sciences
Science & Technology
Life Sciences & Biomedicine
Economics
Health Care Sciences & Services